TIDE exhibits a better performance in evaluating the efficacy of first-line ICI therapy in melanoma patients compared with the widely used biomarkers for ICI therapy, such as tumor mutation burden and PD-L1 expression. This evidence concerns the gene CD274 and melanoma.